Dataset Information

DNAJB9 promotes epithelial-mesenchymal transition in the nasal epithelium of chronic rhinosinusitis by enhancing TRIM22-mediated IκBα degradation

ABSTRACT: This study investigates the functional role of DNAJB9 in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). Using quantitative proteomics alongside human tissue analysis and murine models, we found that DNAJB9 is significantly upregulated in CRSwNP nasal epithelium and closely mirrors epithelial-mesenchymal transition (EMT) progression. Functional assays in human epithelial cells demonstrated that DNAJB9 actively drives the EMT phenotype. Mechanistically, DNAJB9 interacts with and stabilizes the E3 ubiquitin ligase TRIM22 by inhibiting its autoubiquitination. This stabilized TRIM22 targets IκBα for proteasomal degradation, leading to constitutive NF-κB pathway activation and subsequent EMT. Ultimately, DNAJB9 acts as an essential driver of tissue remodeling in CRSwNP. These findings highlight the broader clinical significance of the DNAJB9/TRIM22/NF-κB signaling axis, presenting it as a promising therapeutic target for inhibiting nasal polyp formation and associated remodeling.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Skin

SUBMITTER: Zhiqiang Zhang

LAB HEAD: zhiqiang zhang

PROVIDER: PXD079333 | Pride | 2026-06-17

REPOSITORIES: Pride

ACCESS DATA

Similar Datasets

Project description:Lobaplatin is a third-generation platinum-based antineoplastic agent and is widely used for osteosarcoma treatment before and after tumor removal. However, treatment failure often results from lobaplatin drug resistance. In our study, we found that SaOS-2 and SOSP-9607 osteosarcoma cells became less sensitive to lobaplatin after treatment with exogenous interleukin (IL)-6. Quantitative proteomic analysis was performed to elucidate the underlying mechanism in SaOS-2 osteosarcoma cells. Cells were divided into a control group (CG), a lobaplatin treatment group (LG) and a recombinant human IL-6 (rhIL-6) and lobaplatin group (rhILG). We performed three biological replicates in each group to compare the differential protein expression between groups using tandem mass tag (TMT) labeling technology based on liquid chromatography–tandem mass spectrometry (LC-MS/MS). A total of 1,313 proteins with significantly differential expression were identified and quantified. The general characterizations of significantly enriched proteins were identified by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, and protein-protein interaction (PPI) analysis was conducted using IntAct and STRING. In total, 31 proteins were further verified by parallel reaction monitoring (PRM), in which Ras GTPase-activating protein-binding protein 1 (G3BP1), fragile X mental retardation syndrome-related protein 1 (hFXR1p) and far upstream element-binding protein 1 (FUBP1) were significantly differentially expressed. Immunohistochemistry results showed that these three proteins are highly expressed in specimens of platinum-resistant osteosarcoma patients, while the proteins are negatively or weakly expressed in specimens of platinum-sensitive osteosarcoma patients. The results of immunofluorescence staining were in accordance with those of immunohistochemistry staining. This is the first proteomic study on rhIL-6 intervention before lobaplatin treatment in osteosarcoma cells.

			Action	DRS
	1.raw	Raw
	10.raw	Raw
	2.raw	Raw
	3.raw	Raw
	4.raw	Raw

Dataset Information

DNAJB9 promotes epithelial-mesenchymal transition in the nasal epithelium of chronic rhinosinusitis by enhancing TRIM22-mediated IκBα degradation

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets